Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

regorafenib 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Filgrastim 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1tovorafenib 1pembrolizumab 1entinostat 1aflibercept 1Thiotepa 1Thalidomide 1Temozolomide 1Tamoxifen 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1NEO212 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Immunotherapy 1IFL protocol 1Flucytosine 1Fentanyl 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × tovorafenib × Head & Neck × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡